SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases
This study aimed to evaluate the use of SHR-A1811 and bevacizumab in HER2-positive Breast Cancer with brain metastases
Breasr Cancer
DRUG: SHR-A1811|DRUG: Bevacizumab
CNS-ORR, CNS-ORR was defined as percentage of participants with CNS response assessed by the investigator according to RANO-BM criteria, Up to 2 years
PFS, PFS was defined as the time from first dose to first documented disease progression (PD) or death from any cause, whichever occurred first, up to 2 years|ORR, ORR was defined as percentage of participants with best (confirmed) overall response (BOR) of either CR or PR assessed by the investigator according to RECIST version 1.1, Up to 2 years|AE, Proportion of participants experienced adverse events during the study period, Up to 2 years
This study aimed to evaluate the use of SHR-A1811 and bevacizumab in HER2-positive Breast Cancer with brain metastases